NTLAIntellia Therapeutics, Inc.
Price
-16%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
Intellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Intellia Therapeutics, Inc. (NTLA) reported revenue of $7.7M in Q2 2026 (quarter ended Jun 30, 2026), down 46% from the same quarter a year earlier. That came with net loss of $107M. For the full year FY2025, revenue was $68M (+17% year on year) and net income −$413M. Its largest product in Q1 2023 (quarter ended Mar 31, 2023) was Research And Development Services at $41M, 100% of the disclosed total, well ahead of Research Materials Shippmet Services at 0.2%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026Also on September 8, 2026, the Company announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Biologics License Application (“BLA”) for lonvoguran ziclumeran (“lonvo-z”) and granted the BLA Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027.Regulation FD disclosure · Form 8-K
- Sep 4, 2026On September 4, 2026 (the “Closing Date”), Intellia Therapeutics, Inc. (the “Company” or “Intellia”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent (“Administrative Agent”)Material agreement entered · Form 8-K
- Aug 6, 2026Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q1 2023 · $40.8MThe company’s own SEC segment disclosure.
- Research And Development Services$40.7M100%
- Research Materials Shippmet Services$100.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.